An overview of PsoProtect’s current data.

Current Data

We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.

0
Total number of cases reported

Summary data from PsoProtect’s first 200 cases.

Cases reported by continent:

Continent Cases
Europe 185
South America 10
Asia 3
North America 2

Average age: 50 years
Phenotype of psoriasis: 194 (97%) plaque psoriasis, 4 (2%) generalized pustular psoriasis, 3 (1.5%) erythrodema
Average BMI: 30 kg/m2
Average number of days of symptoms from COVID-19: 17 days

Confirmed COVID-19:

Gender:

Smoking history:

Concurrent psoriatic arthritis:

Severity of psoriasis at time of onset of COVID-19 (PGA):

Psoriasis severity change during COVID-19:

Systemic medication for psoriasis at time of onset of COVID-19:

Medication Count
Standard systemic agent 25
Small molecule inhibitor 12
TNF inhibitor 43
IL-17 inhibitor 46
IL-23p19 inhibitor 17
IL-12/IL-23 inhibitor 35
Biologic and standard systemic co-therapy 7
None 15

Was the biologic medication for psoriasis stopped during COVID-19 infection:

Hospitalization required due to COVID-19:

Outcome of COVID-19: